1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CVR Energy's president and chief executive, Mark Pytosh, stepped down from the company and its board effective June 18, 2026, and Dane Neumann, the former chief financial officer, was appointed to those roles. Richard Roberts was named interim chief financial officer, so both top executive and finance posts changed at once. The filing sets out Pytosh's separation payment and new compensation terms for Neumann, which shareholders can review in the exhibits.
Mark Pytosh's separation agreement provides a $3 million payment, with $1.5 million due within 15 days after the release becomes effective and $1.5 million due 15 days after the nine-month anniversary of that date.
Dane Neumann's employment agreement sets an annual base salary of $800,000 and a target annual bonus of 150% of base salary.
Neumann received a one-time grant of 27,372 performance share units that vest only upon consummation of a Significant Transaction.
Richard Roberts was appointed interim chief financial officer effective June 18, 2026.
Mark Pytosh stepped down as CEO of CVR GP, the general partner of CVR Partners, effective June 18, 2026, and left his CVR Energy roles. CVR Energy and CVR GP appointed Chief Financial Officer Dane Neumann as President and CEO, making him the Partnership's principal executive officer, and named Richard Roberts Interim Chief Financial Officer. The filing does not report financial results or guidance, so the change is a leadership transition with no stated effect on operations.
Pytosh's separation payment totals $3,000,000, paid in two $1,500,000 lump sums, with the second after the nine-month anniversary of the release date; his non-compete period was cut from 18 to 9 months.
Neumann's base salary is $800,000, with a target annual bonus of 150% of salary and a 150% of salary target for annual long-term incentive awards.
Neumann received a one-time award of 27,372 performance share units that vest only if a Significant Transaction is completed within 12 months of the June 22, 2026 grant date.
Roberts, age 43, has worked in CVR Energy's finance organization since 2019 and previously spent over ten years in equity research.
Lionheart Holdings shareholders approved an amendment extending the deadline to complete a business combination from June 20, 2026 to March 20, 2027, and the company filed the amendment in the Cayman Islands on June 22, 2026. The company also entered non-redemption agreements covering 15,879,072 Class A ordinary shares, in exchange for 3,175,814 additional shares to be issued at the closing of a business combination.
Business combination deadline extended from June 20, 2026 to March 20, 2027
Non-redemption agreements cover an aggregate of 15,879,072 Class A ordinary shares held by unaffiliated institutional investors
Holders to receive 3,175,814 additional Class A ordinary shares upon closing of an initial business combination
Sponsor Lionheart Sponsor, LLC did not enter into non-redemption agreements, contrary to the company's June 10, 2026 filing
FB Bancorp and Fidelity Bank informed Chief Operating Officer Randall L. Baker on June 16, 2026 that he would be separated from the bank effective that day. He is entitled to compensation and benefits under the Fidelity Bank Executive Severance Plan, and a separation agreement with a customary release of claims will be filed with the company's Form 10-Q for the period ending June 30, 2026.
Randall L. Baker, Chief Operating Officer, separated from Fidelity Bank effective June 16, 2026
Severance terms follow the Fidelity Bank Executive Severance Plan, described in the most recent proxy statement
A separation agreement with a customary release of claims is expected and will be filed with the Form 10-Q for the period ending June 30, 2026
Oxbridge Re Holdings entered an at-the-market sales agreement on June 22, 2026, with Chardan Capital Markets LLC, allowing it to sell ordinary shares through the agent over time. The deal replaces a prior agreement with Maxim Group LLC that was terminated on June 20, 2026, and sales are not required; shareholders could see dilution if shares are sold.
Shares with an aggregate offering price of up to $1,678,301 were registered under a Form S-3 shelf (File No. 333-287186).
Chardan will receive a commission of 3.0% of gross proceeds from any shares sold.
Net proceeds are intended for general corporate purposes, including funding reinsurance operations.
The company is not obligated to sell any shares under the agreement.
NeoGenomics completed a $316.25 million offering of 0.75% convertible senior notes due 2032, including an option exercised by the initial purchasers for $41.25 million. The company also used about $263.19 million to repurchase about $276.0 million of its 0.25% convertible notes due 2028, and it used about $28.7 million of offering proceeds for capped call transactions meant to reduce potential dilution.
Notes total $316.25 million, with interest of 0.75% per year payable semiannually, maturing July 1, 2032
Initial conversion price is about $14.16 per share, a 35.0% premium to the $10.49 closing price on June 16, 2026
Up to 30,147,733 shares may be issued on conversion; the company may settle conversions in cash, shares, or both
Concurrent repurchase of about $276.0 million of 2028 notes for about $263.19 million, including accrued interest
A. O. Smith announced that Executive Chairman Kevin Wheeler will retire effective July 1, 2026, and remain on the board. CEO Stephen Shafer will become chairman at that time while continuing as president and CEO, combining the two roles under one executive.
Kevin Wheeler retires as Executive Chairman effective July 1, 2026, and remains a board member
Stephen Shafer, president and CEO since July 1, 2025, becomes chairman upon Wheeler's retirement
Shafer joined the company as president and chief operating officer in March 2024
Lead director Chris Mapes said the combined chairman and CEO role will further strengthen alignment across strategy and operations
Stellus Capital Investment Corp entered a new investment advisory agreement with Stellus Capital Management, LLC on June 22, 2026, the same day Ridgepost Capital, LLC completed its acquisition of the adviser. The filing states the new agreement's terms, including advisory fees and fee calculations, are identical to the prior agreement dated October 26, 2012, apart from its date and term.
Stockholders approved the New Advisory Agreement on June 16, 2026; the company entered into it on June 22, 2026.
The agreement took effect on June 22, 2026, upon the closing of Ridgepost Capital, LLC's acquisition of Stellus Capital Management, which changed control of the adviser.
The initial term is two years from June 22, 2026, then renews year to year if approved annually as required under the 1940 Act.
Ridgepost Capital, LLC's parent, Ridgepost Capital, Inc., is listed on the New York Stock Exchange.
Osprey Bitcoin Trust dismissed Grant Thornton LLP as its independent auditor on June 16, 2026, and engaged Cherry Bekaert LLP on June 17, 2026, for the fiscal year ending December 31, 2026. The filing says Grant Thornton's prior two audit reports contained no adverse opinion, disclaimer, or qualification, and that no disagreements with the auditor were reported, but it notes a material weakness in internal control that has not been fully remediated.
Grant Thornton LLP dismissed effective June 16, 2026; Cherry Bekaert LLP engaged effective June 17, 2026
Grant Thornton's audit reports for fiscal 2024 and 2025 had no adverse opinion, disclaimer, or qualification
Material weakness tied to ineffective oversight of the administrator process led to an audit adjustment for fiscal 2025 and was not fully remediated as of March 31, 2026
Grant Thornton's letter to the SEC dated June 22, 2026 is filed as Exhibit 16.1
On June 22, 2026, NextEra Energy Capital Holdings, a wholly-owned subsidiary of NextEra Energy, sold $3.75 billion in three series of junior subordinated debentures due 2056 and 2066. NEE guarantees the debentures on a subordinated basis, so the sale adds long-term subordinated debt backed by the parent.
Series AA: $1.0 billion due October 1, 2056, initial rate 6.000% through October 1, 2031
Series BB: $1.25 billion due October 1, 2056, initial rate 6.200% through October 1, 2036
Series CC: $1.5 billion due October 1, 2066, initial rate 6.625% through October 1, 2046
Debentures were registered under Securities Act registration statements and filed as exhibits with this 8-K; no earnings results were reported
Primoris lowered its full-year 2026 outlook, citing additional cost overruns and delays on six Renewables projects, and now expects net income of $71.0 million to $101.0 million, down from $223.0 million to $234.0 million. The company also said Chief Operating Officer Jeremy Kinch left on June 22, 2026, with CEO Koti Vadlamudi covering the role during a search, and it reported about $2.0 billion in second-quarter Energy segment awards and about $50 million of share repurchases.
Full-year 2026 net income now expected at $71.0 million to $101.0 million, down from $223.0 million to $234.0 million
Diluted EPS now $1.30 to $1.85 (previously $4.05 to $4.25); Adjusted EBITDA now $275.0 million to $325.0 million (previously $480.0 million to $500.0 million)
Renewables revenue for 2026 expected at about $2.1 billion versus about $3.0 billion in 2025
COO Jeremy Kinch departed June 22, 2026; the company said it was not related to any financial or accounting issue
Ridgepost Capital completed its acquisition of Stellus Capital Management, LLC on June 22, 2026, paying $125 million in cash, 11,191,149 Units and 579,096 Class A common shares at closing. The company drew $139 million on its revolving credit facility to fund the cash portion, leaving about $14 million available, and up to an additional $60 million may be paid as an earnout tied to Stellus's performance in 2027 and 2029, which could dilute existing shareholders if paid in equity.
Closing cash consideration of $125 million, subject to customary adjustments; closing equity of 11,191,149 Units and 579,096 Class A common shares
Up to $60 million additional earnout payable in 2028 and 2030, in Units or Class A shares, with up to 50% payable in cash at the sellers' option
Revolving credit facility drawn $139 million on June 18, 2026; commitments raised by $20 million to $195 million; about $14 million available as of June 22, 2026
Sellers' shares subject to lock-up, with one-third released on each of the first, second and third anniversaries of the closing
Co-founder Ichiro Aoki will resign as President and from the board effective June 29, 2026, as part of a phased retirement, and will remain with the company as Technical Advisor. The board appointed Thomas Schiller, a former CFO who has been a Strategic Advisor since November 2024, as a Class III director effective the same date. The filing reports no disagreement with the company over operations, policies or practices.
Ichiro Aoki resigns as President and board member effective June 29, 2026, as part of a phased retirement plan
Aoki continues as a Technical Advisor after the effective date
Thomas Schiller appointed to the board June 18, 2026, with a term expiring at the 2027 Annual Meeting
Schiller receives a $150,000 base salary and a 30% target cash incentive in his Strategic Advisor role, and no additional director pay or committee seats
Comfort Systems USA announced leadership changes effective July 1, 2026. Craig Sasser, currently Regional Vice President for the Atlantic Region, will become Chief Operating Officer, with a $600,000 base salary and a 90% target bonus, and Briston Blair will become Chief Strategy & Innovation Officer. Trent McKenna will continue as President, and the filing reports no financial results or guidance changes.
Craig Sasser named Chief Operating Officer effective July 1, 2026, with a $600,000 annual base salary and a target bonus of 90% of base salary
Sasser's long-term incentive award has a grant date value equal to 200% of base salary, in restricted stock units
Briston Blair moves from Senior Vice President – Innovation & Strategy to Chief Strategy & Innovation Officer, effective July 1, 2026
Trent T. McKenna will continue to serve as President of the Company
Five9 and Executive Vice President of Product Engineering Panos Kozanian have mutually agreed to begin a transition of his responsibilities, effective June 29, 2026. He is expected to remain in his EVP role through at least September 4, 2026, reporting to a new Chief Technology Officer to be announced by the end of the second quarter of 2026. The filing reports no financial results, and the departure terms are limited to continued severance plan eligibility.
Transition of Panos Kozanian's responsibilities effective June 29, 2026
Kozanian expected to remain EVP of Product Engineering through at least September 4, 2026
He will report to a new Chief Technology Officer, to be announced by end of Q2 2026
Eligible for Key Employee Severance Plan benefits as a Tier 3 participant, unless terminated for cause, subject to a standard release
Best Buy said CFO Matt Bilunas will leave the company effective July 31, 2026, after 20 years with the company, including seven as CFO. The company has engaged an external search firm and expects to name a successor with previous CFO experience, while CEO Corie Barry may provide financial oversight during the transition if needed. The CFO change comes ahead of Jason Bonfig taking over as CEO on November 1, 2026.
Matt Bilunas, Senior EVP, CFO and Enterprise Strategy, departs effective July 31, 2026
Best Buy has engaged an external search firm and expects a successor with prior CFO experience
Jason Bonfig becomes the company's sixth CEO on November 1, 2026
Bilunas will receive separation benefits under the ERISA plan described in the April 30, 2026 proxy statement
Arvinas said its chief medical officer, Noah Berkowitz, will leave the company effective July 3, 2026, and it has started a search for a replacement. Under a separation agreement signed June 22, 2026, he will receive nine months of base salary continuation, up to nine months of health premium support, and accelerated vesting of certain restricted stock units.
Chief medical officer Noah Berkowitz departs effective July 3, 2026, and will remain in the role until then.
Severance includes nine months of base salary continuation and up to nine months of health coverage premium payments.
Certain RSUs that would have vested on or before May 9, 2027 will vest early; other unvested RSUs will be forfeited.
The full separation agreement is expected to be filed with the Form 10-Q for the quarter ending June 30, 2026.
PagerDuty appointed Eric Prengel as Chief Financial Officer effective June 22, 2026, succeeding Howard Wilson, who had been CFO since 2016. Wilson will serve as a Strategic Advisor until no later than February 28, 2027. The filing also discloses Prengel's offer letter, including base salary, target bonus, and equity awards, which matter to shareholders because they set the pay terms for the company's top finance executive.
Eric Prengel appointed CFO effective June 22, 2026; he was Global Vice President of Finance at Elastic N.V. from January 2023 until June 2026.
Howard Wilson ceased serving as CFO on June 22, 2026, and will serve as Strategic Advisor until no later than February 28, 2027.
Offer letter sets a $460,000 annual base salary, a target bonus of 75% of base salary, a 600,000-share restricted stock unit award, and a 300,000-share performance award at target.
TaskUs appointed Rishabh Khemka as Chief Financial Officer, effective June 19, 2026, succeeding Trent Thrash, who had served as interim CFO since March 2026. Mr. Khemka previously served as CFO of Encora and spent more than 18 years in finance roles at Wipro. The filing sets out his compensation, including a $550,000 base salary and a $1,000,000 sign-on bonus, which shareholders can review in the company's disclosures.
Base salary of $550,000, with an annual bonus eligibility of up to 80% of base salary; the 2026 bonus is guaranteed to be no less than 40% of earned base salary.
$1,000,000 sign-on bonus, subject to repayment of the unearned balance if employment ends before the third anniversary of his start date.
2026 equity grant on July 15, 2026: RSUs valued at $500,000 and PSUs valued at $333,333, with a target annual equity value of $1,000,000 from 2027.
Trent Thrash continues as Senior Vice President of Corporate Development, Investor Relations and Treasury, reporting to Mr. Khemka.
Adaptive Biotechnologies issued $345 million of 0% convertible senior notes due 2031 on June 22, 2026, including an additional $45 million exercised by the initial purchasers. The company used $156.9 million of the net proceeds to repay its OrbiMed revenue interest purchase agreement, which ends its quarterly revenue-based payments to OrbiMed, and used part of the proceeds for a share repurchase and a capped call transaction.
Notes issued June 22, 2026: $345 million principal, including the $45 million option exercised June 17, 2026; net proceeds of about $334.5 million
$156.9 million used to repay all obligations under the OrbiMed Purchase Agreement, with the revenue interests terminated
Initial conversion price of about $24.11 per share, a 40.0% premium over the $17.22 closing price on June 16, 2026; notes mature July 1, 2031
About $25.0 million used to repurchase 1,451,800 shares of common stock in privately negotiated transactions
On June 22, 2026, People entered a Voting Agreement with Barry Diller, Diane von Furstenberg and Alexander von Furstenberg, who have or may be deemed to have the right to direct voting of about 46.4% of People's outstanding voting power. The agreement requires shares above 48.5% of voting power to be voted in the same proportion as other stockholders, and the Board approved authorization to repurchase an additional 10 million shares, though People is not currently repurchasing shares.
Voting Agreement parties have or may be deemed to have voting control over about 46.4% of People's voting power; shares above 48.5% must vote proportionally with other holders.
The agreement terminates automatically if the parties and their affiliates own less than 30% of voting power or if a change of control occurs.
The Board authorized repurchase of an additional 10 million shares of People Common Stock; People is not currently conducting repurchases.
Christopher Currier was appointed Chief Accounting Officer effective June 16, 2026, succeeding Michael H. Schwerdtman, who retired.
At its June 18, 2026 annual meeting, STAAR Surgical shareholders approved Amendment No. 2 to the company's Omnibus Equity Incentive Plan, increasing the shares reserved for issuance under the plan by 3,900,000. Shareholders also elected all seven director nominees, ratified BDO USA as auditor, and approved the advisory vote on executive compensation. The plan increase adds shares available for equity awards, which can dilute existing shareholders' ownership.
Plan amendment approved: 40,231,475 votes for, 974,989 against, 67,857 abstentions, and 2,406,114 broker non-votes.
All seven directors elected to terms expiring at the 2027 annual meeting; Neal C. Bradsher received 40,776,719 votes for.
BDO USA, P.C. ratified as independent auditor for the fiscal year ending January 1, 2027, with 43,433,234 votes for.
Quorum of 43,680,435 of 49,788,295 outstanding shares as of the April 20, 2026 record date.
Russell Weiner will step down as Domino's CEO on September 30, 2026, and become Executive Chairman after the 2027 annual shareholder meeting. Chief Operating Officer Joe Jordan, age 53, was appointed CEO effective October 1, 2026, and will join the Board, while David Brandon retires from the Board and as Executive Chairman. The filing describes a planned succession, and it does not include financial results or guidance.
Weiner remains CEO through September 30, 2026; Jordan becomes CEO effective October 1, 2026.
Jordan's employment agreement provides a $925,000 annual base salary and a 200% target annual incentive bonus.
Jordan's agreement includes RSUs with a target value of approximately $3,000,000, vesting annually over five years.
Brandon will not stand for re-election at the 2027 annual meeting, expected on or about April 27, 2027.
Ennis reported results for the quarter ended May 31, 2026, with revenue of $98.6 million, up 1.4% from the prior-year quarter, and diluted earnings per share of $0.39 versus $0.38. The company also declared a quarterly dividend of 25.0 cents per share, payable August 10, 2026, and set its 2026 annual shareholder meeting for July 16, 2026.
Revenue $98.6 million vs. $97.2 million a year earlier, up 1.4%
Net earnings $9.9 million, or $0.39 per diluted share, vs. $0.38 a year earlier
Gross profit margin 31.5% vs. 31.1%; operating cash flow $21.2 million vs. $8.0 million
Quarterly dividend of 25.0 cents per share declared June 19, 2026, payable August 10, 2026 to holders of record July 10, 2026
Johnson Outdoors appointed Asad Rahman, formerly Vice President of Finance at Mars, Incorporated, as Vice President and Chief Financial Officer effective June 30, 2026. Current CFO David W. Johnson, who previously announced his retirement, steps down from those roles on the same date but will remain an employee through the end of fiscal 2026 to assist the transition.
Asad Rahman, age 48, becomes CFO and principal financial and accounting officer effective June 30, 2026
David W. Johnson steps down as CFO effective June 30, 2026 and stays employed through the fiscal year ending October 2, 2026
Rahman receives restricted stock valued at $200,000 under the Long-Term Stock Incentive Plan, vesting June 30, 2028
AeroVironment said its previously issued financial statements for the three and nine months ended January 31, 2026 require restatement after an error in the goodwill impairment analysis for its Space reporting unit. The restated figures show a larger net loss and loss from operations, and management found a newly identified material weakness in internal control over financial reporting. Separately, directors David Wodlinger and Henry Albers resigned from the Board effective June 17, 2026, leaving the Board with eight directors.
Net loss was understated by $87,272,000 for the three and nine months ended January 31, 2026; loss from operations was understated by $89,402,000.
Basic and diluted net loss per share was understated by $1.75 for the three months and $1.79 for the nine months ended January 31, 2026.
Management identified a material weakness in controls over the goodwill impairment analysis and concluded disclosure controls were ineffective as of January 31, 2026.
Directors David Wodlinger and Henry Albers resigned effective June 17, 2026; the Arlington Capital shareholder may designate two successors, and none had been designated as of the filing date.
Reinsurance Group of America named Laura Cockrill, its Chief Strategy Officer, as Executive Vice President and Chief Financial Officer effective June 22, 2026. She succeeds Axel André, who resigned effective July 17, 2026, to pursue a new opportunity, according to the company.
Laura Cockrill, 49, becomes EVP and CFO effective June 22, 2026; she had been Chief Strategy Officer since September 2025.
Cockrill joined RGA in 2000 and previously served as Deputy Chief Financial Officer.
Axel André, EVP and CFO, informed the company of his resignation on June 15, 2026, effective July 17, 2026.
The company announced the changes in a June 22, 2026 press release (Exhibit 99.1). CEO Tony Cheng praised Cockrill's finance and strategy experience.
Agilysys, Inc. entered a new employment agreement on June 18, 2026 with CEO and President Ramesh Srinivasan, setting a three-year initial term with automatic one-year renewals. The package includes a $600,000 base salary and a grant of 78,269 restricted stock units valued at $6.8 million, half of which are tied to stock price targets of $105, $120 and $135 per share.
Base salary of $600,000 per year; target annual bonus equal to base salary, with a maximum of 150% of base salary, payable in shares
RSU grant of 78,269 units on June 18, 2026, equal to $6.8 million divided by the 20-day VWAP on that date
Half of the grant (39,135 RSUs) is performance-based, vesting in thirds at 20-day VWAP targets of $105, $120 and $135 per share, subject to continued employment through the second anniversary of the grant date
Severance on termination without cause, for good reason, or after certain non-renewal notice includes two years of base salary and two times target bonus shares
LifeMD entered into agreements with Antares Pharma, a subsidiary of Halozyme, to co-market a direct-to-patient self-pay program for XYOSTED, a testosterone injection. LifeMD will be the exclusive telehealth co-marketing partner, and its pharmacy will be the preferred dispensing pharmacy. The filing does not disclose financial terms or dollar amounts for the deal, so its near-term effect on LifeMD's results cannot be measured from this filing.
The program launches in July 2026 and will initially be available in 37 states.
The company's all-inclusive program price is approximately $249 per month, covering medication and care, per the attached press release.
The agreements have an initial three-year term with automatic one-year renewals unless either party gives 90 days' written notice.
Either party may terminate the Statement of Work if budgeted marketing investments are missed for two consecutive quarters.
CACI International named Dr. Dave Young, 45, as Chief Operating Officer, reporting to CEO John Mengucci. He previously led National Security Space at Lockheed Martin, a business with about $7 billion in revenue last year, according to the press release. The filing says his pay includes a $500,000 sign-on bonus and a $2,000,000 restricted stock unit grant.
Dr. Dave Young, 45, to serve as Chief Operating Officer and report to CEO John Mengucci
Sign-on bonus of $500,000 and restricted stock units valued at $2,000,000, vesting in three equal annual installments from the first anniversary of employment
Most recently General Manager of National Security Space at Lockheed Martin, December 2024 to June 2026; previously COO of CAES from January 2021 to September 2024
Taysha Gene Therapies said it has completed dosing of 17 patients in its REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term data from the Part A trials. The company said the data show gains in developmental milestones at 12 months and beyond, with no treatment-related serious adverse events reported, but the results are company-reported, come from small patient groups, and do not yet include an FDA decision on a BLA submission.
Dosing completed for 17 patients in the REVEAL pivotal trial; topline data from the 6-month interim analysis and FDA feedback expected in the first half of 2027.
100% of 12 REVEAL Part A patients gained or regained at least one developmental milestone by 12 months after treatment.
310 functional gains were observed at 12 months or more after treatment (about 26 per patient), including 31 developmental milestones.
No treatment-related serious adverse events or dose-limiting toxicities reported as of the June 2026 data cutoff (N=29).
Booz Allen agreed on June 19, 2026 to buy Ultra I&C Mission Solutions, a defense technology business, from Ultra Electronics for $720 million, subject to adjustments and customary closing conditions. The filing says the deal is expected to close in the second quarter of fiscal 2027, and that the company believes its liquidity and financing options are sufficient to complete it.
Purchase price is $720 million, subject to certain adjustments, under a stock purchase agreement dated June 19, 2026
Closing expected in the second quarter of fiscal 2027, which ends September 30, 2026; either party may terminate if not closed by December 19, 2026
Booz Allen expects the acquired business's revenue to grow at a strong double-digit rate for several years, with EBITDA margins well above 20%
On June 18, 2026, United Natural Foods and its co-borrowers entered Amendment No. 5 to their Term Loan Agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment reduces the margin over SOFR on the approximately $371 million outstanding term loan from 4.75% to 4.00%, and all other material terms are unchanged. The change lowers the spread on the company's secured term debt, though the filing does not quantify any effect on interest expense.
Amendment No. 5 to the Term Loan Agreement dated October 22, 2018 was entered on June 18, 2026
Applicable margin over SOFR reduced from 4.75% to 4.00% on approximately $371 million outstanding
JPMorgan Chase Bank, N.A. serves as administrative and collateral agent
Full amendment to be filed as an exhibit to the Form 10-K for the year ended August 1, 2026
Arcosa agreed on June 21, 2026 to merge with a subsidiary of CRH Americas, with Arcosa surviving as a wholly owned CRH subsidiary. Each Arcosa common share would convert into $150.00 in cash, and the deal needs approval from a majority of Arcosa stockholders and regulatory clearances, with closing expected in Q1 2027. Shareholders would receive cash rather than continued ownership of Arcosa stock, and the 8-K sets out termination fees payable in both directions.
Merger consideration of $150.00 per share in cash, per the merger agreement; CRH's press release says the offer implies a 25% premium to Arcosa's 60-day trading VWAP as of June 18, 2026
Termination fee of $371,967,952 payable by CRH Americas in certain regulatory-failure cases, and $260,377,567 payable by Arcosa in certain cases including a superior proposal or change of board recommendation
Outside Date of June 21, 2027, extendable by up to six months if only antitrust or regulatory conditions remain unsatisfied
CRH press release says closing is expected in Q1 2027 and the deal is funded with available cash and committed debt financing
Ligand Pharmaceuticals announced a proposed private placement of $550 million in convertible senior notes due 2031, subject to market conditions, and amended its credit agreement to permit the notes and set new minimum Consolidated EBITDA levels. The company plans to use up to $75 million of net proceeds to repurchase common stock from certain note purchasers, and the interest rate and conversion terms will be set at pricing.
Proposed $550 million aggregate principal of convertible senior notes due September 15, 2031, offered privately to qualified institutional buyers; initial purchasers may buy up to an additional $82.5 million within a 13-day option period
Up to $75 million of net proceeds may be used to repurchase common stock from certain note purchasers in privately negotiated transactions
Fourth Amendment to the Credit Agreement sets minimum Consolidated EBITDA of $100 million for the four quarters ending June 30, 2026 through March 31, 2027, and $150 million for later periods
AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, a total equity value of about $10.9 billion, according to a June 22, 2026 joint press release. The deal is expected to close in the third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals, and AbbVie expects it to be accretive to adjusted diluted earnings per share beginning in 2032.
Price: $135.11 per Apogee share in cash; total equity value of about $10.9 billion
Expected closing: third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals
Accretion to AbbVie adjusted diluted EPS expected beginning in 2032
Fairmount Funds Management LLC and Venrock Associates have signed voting agreements supporting the deal
MapLight Therapeutics reported topline results from its Phase 2 IRIS trial of ML-004 in autism spectrum disorder, announced June 22, 2026. The study did not meet its primary endpoint on social communication deficits, but a prespecified analysis in adolescents with moderate-to-severe irritability showed improvement over placebo, and the company plans to meet with the FDA to determine the development path.
Primary endpoint (ABI-SC social communication domain) was not met; no statistical separation from placebo on that measure.
In adolescents with baseline ABC-I score of 16 or higher (N=20), care-partner-reported ABC-I improved over placebo: effect size 1.33, nominal p=0.013.
Two adolescents (3.9%) on ML-004 discontinued due to an adverse event versus none on placebo; no severe or serious adverse events occurred with ML-004.
The company expects to engage the FDA in an End-of-Phase 2 meeting; the trial enrolled 161 participants, including 102 adolescents.
HawkEye 360 reported first quarter 2026 results for the period ended March 31, with record revenue of $49.8 million, up 116.5% from $23.0 million a year earlier. The net loss widened to $9.0 million from $1.6 million, and backlog fell to $285.0 million from $302.7 million at year-end 2025. The company also completed an initial public offering in May 2026 that generated $435.9 million in net proceeds, and it will provide its 2026 outlook with its second quarter results.
Total revenue was $49.8 million, up 116.5% from $23.0 million in the prior-year period.
Net loss was $9.0 million, compared with $1.6 million a year earlier; adjusted EBITDA, a non-GAAP measure, was $7.4 million.
Backlog was $285.0 million at March 31, 2026, down from $302.7 million at December 31, 2025.
The IPO sold 18.4 million shares at $26.00 per share, generating net proceeds of $435.9 million.
CRH agreed on June 21, 2026 to acquire Arcosa, Inc. through a merger in which Arcosa becomes a wholly owned subsidiary, with Arcosa stockholders to receive $150.00 in cash per share. The deal is expected to close in Q1 2027, subject to Arcosa stockholder approval, regulatory approvals and customary conditions, and CRH plans to fund it with available cash and committed debt financing.
Price of $150.00 per share in cash, a 25% premium to Arcosa's 60-day trading VWAP as of June 18, 2026; enterprise value of approximately $8.5 billion
Termination fee of $371,967,952 payable by Parent in certain regulatory-failure circumstances; $260,377,567 payable by Arcosa in certain circumstances
Outside Date of June 21, 2027, extendable by up to six months if only antitrust or regulatory conditions remain unsatisfied
CRH expects $175 million of run-rate cost synergies by year three and pro forma FY 2026E net debt to Adjusted EBITDA of 2.4x
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.